Scinai Immunotherapeutics (SCNI) EPS (Weighted Average and Diluted) (2021 - 2024)

Scinai Immunotherapeutics has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting -$0.0 for Q4 2024.

• EPS (Weighted Average and Diluted) for Q4 2024 came in at -$0.0, up 39.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $0.0 (up 232.63% YoY), and the FY2025 annual result was $0.0, up 133.61% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.0 for Q4 2024 at Scinai Immunotherapeutics, up from -$2.9 million in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.03 in Q4 2021 to a low of -$2.9 million in Q2 2024.
• The 4-year median for EPS (Weighted Average and Diluted) is -$0.0 (2022), against an average of -$420214.3.
• Across the five-year window, EPS (Weighted Average and Diluted) tumbled 190.82% in 2022 and soared 95.39% in 2023, its largest moves.
• Scinai Immunotherapeutics' EPS (Weighted Average and Diluted) stood at $0.03 in 2021, then tumbled by 190.82% to -$0.03 in 2022, then jumped by 95.39% to -$0.0 in 2023, then soared by 39.86% to -$0.0 in 2024.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.0 (Q4 2024), -$2.9 million (Q2 2024), and -$0.0 (Q4 2023), per Business Quant data.